Control of Myopia in Young Children Using H.O.P.E. Lenses Combined With 0.02% Atropine Eye Drops
Key facts
- Who runs it
- Ruihua Wei
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 264 people, planned
- Started
- 30 Sept 2026
- Expected to end
- 20 Sept 2028
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- High-order Phase Element Array Microstructure Design Lens (H.O.P.E.)
- 0.02% Atropine Sulfate Eye Drops
- Record updated
- 29 September 2026
Who can take part
- Age
- 6 years to 9 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age: 6-9 years old (6 years old but under 10 years old), gender not restricted
- Clinically diagnosed with bilateral myopia (after cycloplegia), refractive error within -6.00D < SER ≤ -0.50D, astigmatism ≤ 1.50D, refractive anisometropia ≤ 1.50D (based on subjective refraction values)
- Corrected visual acuity LogMAR ≤ 0.1
- Able to understand the research purpose, voluntarily participate, and the subject and his/her legal guardian sign the informed consent form
Who cannot take part
- Those who have participated in other clinical trials or studies related to myopia control within 90 days before signing the informed consent form
- Those who have used myopia control products within 90 days before signing the informed consent form (such as near-axial lenses, low-concentration atropine eye drops, corneal reshaping lenses, red light, etc.)
- Those who cannot wear glasses regularly or use the medication as required (such as having a significant difference in compliance)
- Those who have discontinued the use of atropine eye drops (due to glaucoma or a tendency towards glaucoma, or are allergic to scopolamine or the components of this product)
- Those currently suffering from any of the following diseases that may affect vision or refractive errors, or ocular organic diseases: such as diseases causing damage to the lens like cataracts, glaucoma, macular degeneration, corneal diseases, uveitis, retinal detachment, severe vitreous opacity, acute/chronic keratitis, conjunctivitis, irregular cornea, keratoconus, manifest strabismus, fundus diseases, etc.; systemic diseases that may affect the eyes, such as immune system diseases, central nervous system diseases, Down syndrome, asthma, epilepsy, severe heart or lung function disorders, severe liver or kidney function impairments, etc
- If a subject meets any of the following exclusion criteria, they will not be included in this study:
- During the screening period, the intraocular pressure of either eye is greater than 21 mmHg or less than 10 mmHg, or the intraocular pressure difference between both eyes is ≥ 5 mmHg
- There is a severe abnormality in the accommodative function (accommodative amplitude < 8D)
- Only one eye meets the inclusion criteria
- Other situations that the researcher deems unsuitable for participating in this study
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 6 and 9 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A multicenter, prospective, intervention study on the control of myopia in young children using high-order phase element array microstructure lenses (H.O.P.E.) in combination with low-concentration atropine eye drops (0.02%)
The 3 groups in the trial
- Group A (H.O.P.E. Lens Group)Existing treatment, for comparison
Wearing H.O.P.E. lens frame glasses (provided by Shenyang Kangnd Medical Technology Co., Ltd.)
Treatment: High-order Phase Element Array Microstructure Design Lens (H.O.P.E.)
- Group B (0.02% Atropine group)Existing treatment, for comparison
Use 0.02% atropine sulfate eye drops (provided by Shenyang Xingqi Eye Pharmaceuticals Co., Ltd.)
Treatment: 0.02% Atropine Sulfate Eye Drops
- Group C (H.O.P.E. lenses + 0.02% atropine group)Treatment being tested
Wearing H.O.P.E. lens frame glasses (provided by Shenyang Kangnd Medical Technology Co., Ltd.); Use 0.02% atropine sulfate eye drops (provided by Shenyang Xingqi Eye Pharmaceuticals Co., Ltd.)
Treatment: High-order Phase Element Array Microstructure Design Lens (H.O.P.E.) and 0.02% Atropine Sulfate Eye Drops
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Prospective, Intervention Study on the Control of Myopia in Young Children Using High-order Phase Element Array Microstructure Lenses (H.O.P.E.) in Combination With Low-concentration Atropine Eye Drops (0.02%)
- Criteria questions
- Built from NCT07846787, who can take part
- Record updated
- 29 September 2026